SBI Pharma Fund (D)
|
| Summary Info |
|
Fund Name
|
: |
SBI Mutual Fund
|
|
Scheme Name
|
: |
SBI Pharma Fund (D)
|
|
AMC
|
: |
SBI Mutual Fund
|
|
Type
|
: |
Open
|
|
Category
|
: |
Equity - Pharma
|
|
Launch Date
|
: |
04-Jun-99
|
|
Fund Manager
|
: |
Tanmaya Desai
|
|
Net Assets (Rs. cr)
|
: |
95.21
|
|
|
|
|
|
NAV Date
|
: |
19-Jun-13
|
|
NAV [Rs.]
|
: |
52.7
|
|
Buy/Resale Price [Rs.]
|
: |
52.12
|
|
Sell/Repurchase Price [Rs.]
|
: |
52.65
|
|
Entry Load %
|
: |
Nil
|
|
Exit Load %
|
: |
NIL
|
|
|
|
|
|
|
|
|
|
|
|
Performance(%)
* returns above 1 yr. are annualized
|
|
1w
|
1m
|
3m
|
6m
|
1y
|
3y
|
5y
|
Since INC
|
|
Scheme Returns
|
[0.2] |
[4.0] |
7.7 |
5.6 |
33.4 |
15.6 |
14.7 |
15.6 |
|
Category Avg
|
[0.6] |
[3.4] |
7.8 |
3.5 |
27.9 |
12.0 |
19.5 |
12.3 |
|
Category Best
|
[0.2] |
[2.9] |
8.9 |
5.6 |
33.4 |
15.6 |
24.0 |
24.2 |
|
Category Worst
|
[1.2] |
[4.0] |
7.1 |
2.0 |
25.8 |
10.7 |
14.6 |
1.7 |
|
|
|
|
|
|
|
Dividends
|
Bonus
|
|
Ratio
|
39 % |
NA
|
|
Date
|
31-Dec-04 |
NA
|
|
|
|
|
|
Tax Benefits :
|
54EA |
|
Min. Investment(Rs.) :
|
2,000.00 |
|
Increm.Investment(Rs.) :
|
500.00 |
|
|
|
|
In
|
|
Name of the Company
|
No of shares
|
|
Merck
|
27,000
|
|
Ipca Labs.
|
20,000
|
|
|
|
|
Out
|
|
Name of the Company
|
No of shares
|
|
Ranbaxy Labs.
|
35,000
|
|
Novartis India
|
17,312
|
|
Strides Arcolab
|
10,000
|
|
|
|
|
Fund Holdings
As on 31-May-2013
| Asset Type | Instrument Name | Industry | Net Assets
(%) | No of Shares | Mkt Value
(Cr.) | | Equity & Equity related Investments | | Equity | sun pharmaceuticals industries ltd. | Pharmaceuticals | 20.9 | 180,000 | 17.1 | | Equity | dr. reddy's laboratories ltd. | Pharmaceuticals | 14.1 | 57,000 | 11.5 | | Equity | cipla ltd. | Pharmaceuticals | 11.9 | 240,000 | 9.7 | | Equity | glenmark pharmaceuticals ltd. | Pharmaceuticals | 7.4 | 125,000 | 6.1 | | Equity | divi's laboratories ltd. | Pharmaceuticals | 7.2 | 55,000 | 5.9 | | Equity | wockhardt ltd. | Pharmaceuticals | 7.0 | 30,000 | 5.7 | | Equity | aurobindo pharma ltd. | Pharmaceuticals | 4.7 | 200,000 | 3.8 | | Equity | alembic pharmaceuticals ltd. | Pharmaceuticals | 3.5 | 250,000 | 2.9 | | Equity | lupin ltd. | Pharmaceuticals | 3.4 | 40,000 | 2.8 | | Equity | cadila healthcare ltd. | Pharmaceuticals | 2.9 | 30,000 | 2.4 | | Equity | wyeth ltd. | Pharmaceuticals | 2.0 | 20,000 | 1.6 | | Equity | ranbaxy laboratories ltd. | Pharmaceuticals | 1.9 | 35,000 | 1.6 | | Equity | indoco remedies ltd. | Pharmaceuticals | 1.9 | 250,000 | 1.6 | | Equity | torrent pharmaceuticals ltd. | Pharmaceuticals | 1.3 | 15,000 | 1.0 | | Equity | novartis india ltd. | Pharmaceuticals | 1.2 | 17,312 | 1.0 | | Equity | strides arcolab ltd. | Pharmaceuticals | 1.0 | 10,000 | 0.9 | | Equity | shasun pharmaceuticals ltd. | Pharmaceuticals | 0.7 | 80,000 | 0.6 | | Cash & Cash Equivalent | | CBLO | cblo | UR / N.A. | 7.0 | NA | 5.7 | | Cash & Bank Balance & Bank Deposits | cash and bank balances | -/- | 0.4 | NA | 0.3 | | Net CA & Others | net current assets | -/- | [0.3] | NA | [0.2] |
|
|